Cell- and subcellular organelle-targeting nanoparticle-mediated breast cancer therapy

Frontiers in Pharmacology

Pharmacology

Ming Yang¹  Xue Wei² 

[1] Department of Breast Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun, China;Department of Breast Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun, China;Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, China;

关键词: organelle-targeting nanoparticle;    controlled drug delivery;    reversal of drug resistance;    inhibition of metastasis;    breast cancer therapy;   

DOI  :  10.3389/fphar.2023.1180794

 received in 2023-03-06, accepted in 2023-03-27,  发布年份 2023

来源: Frontiers

【 摘 要 】

Breast cancer (BC) is the most prevalent malignant tumor, surpassing lung cancer as the most frequent malignancy in women. Drug resistance, metastasis, and immune escape are the major factors affecting patient survival and represent a huge challenge in BC treatment in clinic. The cell- and subcellular organelle-targeting nanoparticles-mediated targeted BC therapy may be an effective modality for immune evasion, metastasis, and drug resistance. Nanocarriers, efficiently delivering small molecules and macromolecules, are used to target subcellular apparatuses with excellent targeting, controlled delivery, and fewer side effects. This study summarizes and critically analyzes the latest organic nanoparticle-mediated subcellular targeted therapeutic based on chemotherapy, gene therapy, immunotherapy, and combination therapy in detail, and discusses the challenges and opportunities of nanoparticle therapy.

【 授权许可】

Unknown   
Copyright © 2023 Wei and Yang.